Biomarker ID 2465 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2465 |
| Biomarker | GPC3, CAP2, UBD, MT1F, PTDSS1, RDS, ID1, NNMT, AA127809, PRRG2, ACAA1, SLC22A1, BE779749, FACL2, PRLR, C8orf4, C6, CCNH, AK022114, CBFA2T3, EPAS1, API5, SULT2A1, PGM1, C9, NQO1, C1R, PMS1, DSCR1, PPP1R2, GOT1, ZNF6, AI831040, GCLC, MYOZ2, HMGCL, UBE4A, SERPING1, PLG, ADFP, RODH, MARCO, C9orf59, BG71 |
| Biomarker Name/Symbol (given in Publication) | 44-genes-signature (GPC3, CAP2, UBD, MT1F, PTDSS1, RDS, ID1, NNMT, AA127809, PRRG2, ACAA1, SLC22A1, BE779749, FACL2, PRLR, C8orf4, C6, CCNH, AK022114, CBFA2T3, EPAS1, API5, SULT2A1, PGM1, C9, NQO1, C1R, PMS1, DSCR1, PPP1R2, GOT1, ZNF6, AI831040, GCLC, MYOZ2, HMGCL, UBE4A, SERPING1, PLG, ADFP, RODH, MARCO, C9orf59, BG714912) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | 44-gene signature could useful for diagnosis and therapeutic target of HCC and validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed (GPC3, CAP2, UBD Upregulated and rest 41 are Downregulated) in tumor v/s non-tumor |
| Level of significance | p < 0.001 |
| Source | Tissue |
| PMID | 15607117 |
| Type of Biomarker | Diagnostic |
| Pathway | Cell cycle, metabolic pathways, signal transduction |
| Cohort | 68 HBV-associated HCC patients: B-type HCC (n=33) and their corresponding non-tumor liver tissues (n=23); Independent validation dataset of 40 HCC patients (21 non-tumor liver tissues and 19 HCC tissues) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | 90% |
| AUC | NA |
| Disease | HBV-associated HCC |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |